Brochure
An advanced end-to-end solution for rapid CAR-T cell therapy manufacturing, designed to empower investigators and drug developers with automated production capabilities in a closed system. Designed to transform the traditional CAR-T manufacturing paradigm by eliminating the need for long cell expansion, reducing costs, and accelerating the delivery of potent, patient-specific therapies.
With the three-step workflow and compatibility with peripheral blood, leukopaks, and PBMCs, MARS Atlas represents the future of an accessible, efficient, and flexible CAR-T therapy manufacturing platform.
Streamlined manufacturing process bypassing traditional T cell activation and expansion stages reduces T cell exhaustion and preserves cell stemness. The resulting CAR T cells more potent than conventional CAR-T treatments at four weeks post-infusion.
A three-step process, Isolation → Transduction → Purification, produces CAR-T cells within 24 to 48 hours. The rapid approach aims to minimize vein-to-vein time, especially important for critically ill patients and point-of-care settings.
Designed to lower the cost of goods (COGs) through reducing labor, logistical demands, and equipment requirements. The compact, modular system supports small-scale, localized production for enabling widespread adoption and personalized cell therapy access.
Learn about the latest advancements in CAR-T therapy and the future of decentralized manufacturing in our new blog post.
